The Sound of Evolution
Sorafenib
Mechanism of action:
Sorafenib is a multiple tyrosine kinase inhibitor (multiple tyrosine kinase inhibitor). Sorafenib directly inhibits members of the RAF kinase family, including c-RAF and B-RAF. Once RAF is inhibited by sorafenib, tumor cell proliferation is suppressed. Sorafenib also inhibits multiple receptor tyrosine kinases involved in angiogenesis, including VEGFR-2, VEGFR-3, and PDGFR-beta, thereby blocking new blood vessel formation and reducing blood supply to tumors.
Reference(s):
1. Iyer R et al. (2010). Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother.
2. Keating GM et al. (2017). Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol.
3. Keating GM et al. (2009). Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs.